Microdialysis with radiometric monitoring of L-Β-11 CDOPA to assess dopaminergic metabolism: Effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 1, 2011, Pages 124-131

  Okada, Maki ^a,b   Nakao, Ryuji ^a   Hosoi, Rie ^b   Zhang, Ming Rong ^a   Fukumura, Toshimitsu ^a   Suzuki, Kazutoshi ^a   Inoue, Osamu ^b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

catechol O methyltransferase; DOPA decarboxylase; L 11C DOPA; microdialysis; monoamine oxidase

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,5 DINITROCATECHOL; AMINE OXIDASE (FLAVIN CONTAINING); AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE; CARBON 11; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CATECHOLAMINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; HOMOVANILLIC ACID; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DIALYSATE; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MENTAL DISEASE; METABOLITE; MICRODIALYSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RADIOMETRY; RAT; SYNTHESIS;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BENSERAZIDE; BIOTRANSFORMATION; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE AGENTS; ENZYME INHIBITORS; EXTRACELLULAR FLUID; HOMOVANILLIC ACID; LEVODOPA; MALE; MICRODIALYSIS; MONOAMINE OXIDASE INHIBITORS; NEOSTRIATUM; PARGYLINE; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 78650916729     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2010.58     Document Type: Article

References (39)

1. Adachi YU, Satomoto M, Higuchi H, Watanabe K, Yamada S, Kazama T (2005) Halothane enhances dopamine metabolism at presynaptic sites in a calciumindependent manner in rat striatum. Br J Anaesth 95:485-94
2. Ashcroft GW (1969) Amine metabolism in brain. Proc R Soc Med 62:1099-101
3. Benetello P, Furlanut M, Fortunato M, Pea F, Baraldo M (1997) Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Pharmacol Res 35:313-5
4. Bonifacio MJ, Palma PN, Almeida L, Soares-da-Silva P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 13:352-79
5. Cumming P, Gjedde A (1998) Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29:37-61
6. DeJesus OT, Haaparanta M, Solin O, Nickles RJ (2000) 6-FluoroDOPA metabolism in rat striatum: time course of extracellular metabolites. Brain Res 877:31-6
7. Di Stefano A, Sozio P, Iannitelli A, Cerasa LS (2009) New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv 6:389-404
8. Eisenhofer G, Kopin IJ, Goldstein DS (2004a) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331-49
9. Eisenhofer G, Kopin IJ, Goldstein DS (2004b) Leaky catecholamine stores: undue waste or a stress response coping mechanism? Ann N Y Acad Sci 1018:224-30
10. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM (1998) DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 18:5901-7
11. Fernandez HH, Chen JJ (2007) Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 27:174S-85S
12. Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone-a review. J Neural Transm 111:1343-63
13. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22:429-36
14. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34
15. Ikemoto M, Sasaki M, Haradahira T, Yada T, Omura H, Furuya Y, Watanabe Y, Suzuki K (1999) Synthesis of Lbeta-C-11 amino acids using immobilized enzymes. Appl Radiat Isot 50:715-21
16. Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D (1996) Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 16:854-63
17. Ito H, Ota M, Ikoma Y, Seki C, Yasuno F, Takano A, Maeda J, Nakao R, Suzuki K, Suhara T (2006) Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[beta-11C]DOPA. Nucl Med Commun 27:723-31
18. Itoh A, Nitta A, Nadai M, Nishimura K, Hirose M, Hasegawa T, Nabeshima T (1996) Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid protein-infused rats. J Neurochem 66:1113-7
19. Jonkers N, Sarre S, Ebinger G, Michotte Y (2001) Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 108:559-70
20. Jung MC, Shi G, Borland L, Michael AC, Weber SG (2006) Simultaneous determination of biogenic monoamines in rat brain dialysates using capillary high-performance liquid chromatography with photoluminescence following electron transfer. Anal Chem 78:1755-60
21. Lee ES, Chen H, King J, Charlton C (2008) The role of 3-Omethyldopa in the side effects of L-dopa. Neurochem Res 33:401-11
22. Leger G, Gjedde A, Kuwabara H, Guttman M, Cumming P (1998) Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness. Synapse 30:351-61
23. Lindner KJ, Hartvig P, Tedroff J, Ljungstrom A, Bjurling P, Langstrom B (1995) Liquid chromatographic analysis of brain homogenates and microdialysates for the quantification of L-[beta-11C]DOPA and its metabolites for the validation of positron emission tomography studies. J Pharm Biomed Anal 13:361-7
24. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46:681-8
25. Miwa S, Gillberg PG, Bjurling P, Yumoto N, Odano I, Watanabe Y, Langstrom B (1992) Assessment of dopamine and its metabolites in the intracellular and extracellular compartments of the rat striatum after peripheral administration of L-[11C]dopa. Brain Res 578:122-8
26. Nakao R, Okada M, Inoue O, Fukumura T, Suzuki K (2008) Combining high-performance liquid chromatographypositron detection and on-line microdialysis for animal metabolism study of positron emission tomography probes. J Chromatogr A 1203:193-7
27. Napolitano A, Bellini G, Borroni E, Zurcher G, Bonuccelli U (2003) Effects of peripheral and central catechol-Omethyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Parkinsonism Relat Disord 9:145-50
28. Niazi Shahabi H, Bergquist F, Nissbrandt H (2003) An investigation of dopaminergic metabolites in the striatum and in the substantia nigra in vivo utilising radiolabelled L-DOPA and high performance liquid chromatography: a new approach in the search for transmitter metabolites. Neuroscience 120:425-33
29. Okada M, Nakao R, Hosoi R, Zhang MR, Fukumura T, Suzuki K, Inoue O (2009) In vivo monitoring of extracellular 13N-glutamine derived from blood-borne 13N-ammonia in rat striatum using microdialysis with radio-LC method. J Neurosci Methods 184:37-41
30. Paxinos P, Watson C (2004) The Rat Brain in Stereotaxic Coordinates. San Diego, Tokyo: Elsevier Academic Press
31. Robinson DL, Venton BJ, Heien ML, Wightman RM (2003) Detecting subsecond dopamine release with fast-scan cyclic voltammetry in vivo. Clin Chem 49:1763-73
32. Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK (1997) Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. Synapse 27:336-46
33. Sasaki M, Ikemoto M, Mutoh M, Haradahira T, Tanaka A, Watanabe Y, Suzuki K (2000) Automatic synthesis of L-[beta-11C]amino acids using an immobilized enzyme column. Appl Radiat Isot 52:199-204
34. Shou M, Ferrario CR, Schultz KN, Robinson TE, Kennedy RT (2006) Monitoring dopamine in vivo by microdialysis sampling and on-line CE-laser-induced fluorescence. Anal Chem 78:6717-25
35. Silva MA, Mattern C, Hacker R, Tomaz C, Huston JP, Schwarting RK (1997) Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse 27:294-302
36. Smith JE, Co C, Coller MD, Hemby SE, Martin TJ (2006) Self-administered heroin and cocaine combinations in the rat: additive reinforcing effects-supra-additive effects on nucleus accumbens extracellular dopamine. Neuropsychopharmacology 31:139-50
37. Smolders I, Khan GM, Manil J, Ebinger G, Michotte Y (1997) NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis. Br J Pharmacol 121:1171-9
38. Tohgi H, Abe T, Kikuchi T, Takahashi S, Nozaki Y (1991) The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearingoff phenomenon in Parkinson's disease. Neurosci Lett 132:19-22
39. Tsukada H, Lindner KJ, Hartvig P, Tani Y, Bjurling P, Kihlberg T, Westerberg G, Watanabe Y, Langstrom B (1994) Effect of 6R-L-erythro-5,6,7,8- tetrahydrobiopterin on in vivo L-[beta-11C]dopa turnover in the rat striatum with infusion of L-tyrosine. J Neural Transm Gen Sect 95:1-15